Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0945 • ACR Convergence 2025
Nerve Injury-Induced Protein-1 (Ninj1) Deficiency Aggravates Murine Lupus Through Modulation of Macrophage Polarization
Jorge Romo-Tena¹, Luz Blanco², Shuichiro Nakabo³, Victoria Hoffman⁴, Norio Hanata⁵, Mingzeng Zhang², Carmelo Carmona-Rivera⁵, Eduardo Patino-Martinez⁶, Dillon Claybaugh², Zu-Xi Yu² and Mariana Kaplan⁵, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²NIH, Bethesda, MD, ³NIAMS, NIH, Bethesda, MD, ⁴Diagnostic and Research Services Branch, Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶NIH/NIAMS, Bethesda, MD
Background/Purpose: Nerve injury-induced protein-1 (Ninj1) is an adhesion molecule that plays various roles in immune and stromal cells, including the modulation of inflammation and a…
Abstract Number: 0905 • ACR Convergence 2025
Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases
Jinyang Li, Xiu Han, Yi Wang, Yiyi Li, Zhaoru Ma, Yang Li, Zhimin Zhang, Liu Li, Meng Ni, Jiangkun Bi, Xing Yang, Yao Xiong, Shuaixiang Zhou and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Immune reset, achieved through profound and sustained depletion of B cells and/or plasma cells, has demonstrated significant clinical efficacy in patients with severe and…
Abstract Number: 0649 • ACR Convergence 2025
Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
Zhuoli Zhang¹, Shengyun Liu², Min Yang³, Yasong Li⁴, Qinghong Yu⁵, Xinwang Duan⁶, Qiang Shu⁷, Qibing Xie⁸, Yanfei Chen⁹, Daming Ou¹⁰, Lan He¹¹, Hongbin Li¹², Pingting Yang¹³, Juan Li¹⁴, Terry Yan¹⁵, Xin He¹⁶, Daniel Moldaver¹⁷, Ciara O'Shea¹⁸ and Liya Fan¹⁶, ¹Peking University First Hospital, Beijing, Beijing, China (People's Republic), ²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), ³Nanfang Hospital Southern Medical University, Guangzhou, China (People's Republic), ⁴Zhejiang Provincial People's Hospital, Hangzhou, China (People's Republic), ⁵Zhujiang Hospital of Southern Medical University, Zhujiang, China (People's Republic), ⁶The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ⁷Qilu Hospital of Shandong University, Jinan, China (People's Republic), ⁸West China Hospital, Sichuan University, Chengdu, China (People's Republic), ⁹The First Hospital of Lanzhou University, Lanzhou, China (People's Republic), ¹⁰The First Affiliated Hospital of University of South China, Hengyang, China (People's Republic), ¹¹The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China (People's Republic), ¹²The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ¹³The First Hospital of China Medical University, Shenyang, China (People's Republic), ¹⁴The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ¹⁵Medical Affairs, GSK, Shanghai, China (People's Republic), ¹⁶VEO, GSK, Shanghai, China (People's Republic), ¹⁷GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ¹⁸Global Medical Affairs, GSK, Dublin, Ireland
Background/Purpose: Belimumab, a B-cell modulator monoclonal antibody that selectively inhibits BLyS and reduces autoreactive B-cells that drive lupus disease activity, has consistently demonstrated improved efficacy…
Abstract Number: 0629 • ACR Convergence 2025
Characterizing Arthritis Subtypes in SLE: Prevalence, Clinical Features, and the Role of Type I Interferon Signatures
Pankti Mehta¹, Fadi Kharouf², Virginia Carrizo Abarza³, Qixuan Li⁴, Dafna D. Gladman⁵, Zahi Touma⁶ and Laura Whitall Garcia⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: We aimed to study the prevalence of subtypes of lupus arthritis and determine their association with clinical features, serology, and type I interferon signature.Methods:…
Abstract Number: 0612 • ACR Convergence 2025
Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Fadi Kharouf¹, JuanPablo Diaz Martinez², Pankti Mehta³, Dafna D. Gladman⁴, Laura Whitall Garcia⁵ and Zahi Touma⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarials, particularly hydroxychloroquine, are a cornerstone of systemic lupus erythematosus (SLE) management, with well-established benefits including reduced disease activity, prevention of flares, and mitigation…
Abstract Number: 0595 • ACR Convergence 2025
Sustained Remission In SLE Is Infrequent On Standard Of Care: A Decade Of Insights From The Asia Pacific Lupus Collaboration
Rangi Kandane-Rathnayake¹, Yi-Hsing Chen², Alberta Hoi³, Vera Golder⁴, Worawit Louthrenoo⁵, Jiacai Cho⁶, Aisha Lateef⁷, Laniyati Hamijoyo⁸, Shue Fen Luo⁹, Yeong-Jian Jan Wu¹⁰, Chiu Wai Shirley Chan¹¹, Leonid Zamora¹², Yasuhiro Katsumata¹³, Sargunan Sockalingam¹⁴, Zhanguo Li¹⁵, Haihong Yao¹⁵, BMDB Basnayake¹⁶, Yih Jia Poh¹⁷, Yanjie Hao¹⁸, Zhuoli Zhang¹⁹, Madelynn Chan²⁰, Jun Kikuchi²¹, Yuko Kaneko²², Tsutomu Takeuchi²³, Shereen Oon²⁴, Kristine Ng²⁵, Sang-Cheol Bae²⁶, Cherica Tee²⁷, Michael Tee²⁷, Nicola Tugnet²⁸, Sean O’Neill²⁹, Geraldine Hassett³⁰, Fiona Goldblatt³¹, Naoaki Ohkubo³², Yusuke Miyazaki³², Mark Sapsford³³, Yoshiya Tanaka³⁴, Sandra Navarra³⁵, Chak Sing Lau³⁶, Mandana Nikpour³⁷ and Eric Morand³⁸, ¹Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ²Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ³Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ⁴Monash University, Clayton, Australia, ⁵Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, ⁷Woodlands Health, Singapore, Singapore, ⁸Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, ⁹Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), ¹⁰Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan (Republic of China), ¹¹Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ¹²University of Santo Tomas Hospital, Manila, Philippines, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴University of Malaya Medical Center, Kuala Lumpur, Malaysia, ¹⁵Peking University People's Hospital, Beijing, China (People's Republic), ¹⁶National Hospital Kandy, Kandy, Sri Lanka, ¹⁷Singapore General Hospital, Singapore, Singapore, ¹⁸St Vincent’s Hospital Melbourne, Fitzroy, Australia, ¹⁹Peking University First Hospital, Beijing, Beijing, China (People's Republic), ²⁰Tan Tock Seng Hospital, Singapore, Singapore, ²¹Keio University, Tokyo, Japan, ²²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²³Saitama Medical University and Keio University, Tokyo, Japan, ²⁴St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia, ²⁵Health New Zealand Waitemata, Te Whatu Ora, Auckland, New Zealand, ²⁶Hanyang University Medical Center, Seoul, South Korea, ²⁷University of the Philippines, Manila, Philippines, ²⁸Health New Zealand Auckland, Te Whatu Ora (Auckland District Health Board), Auckland, New Zealand, ²⁹The University of Sydney, Sydney, Australia, ³⁰Liverpool Hospital, NSW, Liverpool, Australia, ³¹Flinders Medical Centre, Bedford park, Australia, ³²University of Occupational and Environmental Health, Kitakyushu, Japan, ³³Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital),, Auckland, New Zealand, ³⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³⁵University of Santo Tomas, Manila, Philippines, ³⁶The University of Hong Kong, Hong Kong, Hong Kong, ³⁷University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia, ³⁸Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia
Background/Purpose: Treat-to-target (T2T) states in SLE, such as the Lupus Low Disease Activity State (LLDAS) and remission (REM) as defined by the Definitions of Remission…
Abstract Number: 0801 • ACR Convergence 2025
Achieving Sustained Lupus Low Disease Activity State and Remission With Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A post hoc Analysis From a Phase II Study
Eric Morand¹, Corine Gaillez², Stephen Oliver³, Swati Ghanshani⁴, Marilia Pozzobon⁵, Weibin Bao⁶ and Ed Vital⁷, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Novartis Pharma AG, Basel, Switzerland, Croissy Sur Seine, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ⁵Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁷University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Ianalumab, a fully human monoclonal antibody against the B cell–activating factor receptor (BAFF-R), has a dual mechanism of action of B cell depletion through…
Abstract Number: 0217 • ACR Convergence 2025
Development of the American College of Rheumatology Implementation Guide for Integrating Patient Reported Systemic Lupus Erythematosus Quality Measures
Catherine Nasrallah¹, Christine Hariz², Shanthini Kasturi³, Wambui Machua⁴, Jinoos Yazdany⁵, Christie Bartels⁶, Kate Chiseri⁷, Starla Blanks⁷, Patti Katz⁸, Cherish Wilson⁹, April Jorge¹⁰, Beth Radtke¹¹, Tom Tack⁷ and Shivani Garg¹², ¹University of California San Francisco (UCSF), San Francisco, CA, ²University of California San Francisco (UCSF, San Francisco, CA, ³Tufts Medical Center, Boston, MA, ⁴Piedmont Healthcare, Atlanta, GA, ⁵UCSF, San Francisco, CA, ⁶University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷American College of Rheumatology, Atlanta, GA, ⁸UCSF, San Rafael, CA, ⁹UCSF / SFVA, San Francisco, CA, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹ACR, Atlanta, GA, ¹²University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease that presents unique care challenges. To improve high-quality patient-centered care, the American College of Rheumatology (ACR),…
Abstract Number: 0013 • ACR Convergence 2025
Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
Xiaofeng Zhao¹, Xiaoqing Liu¹, Yuxi Yan², Tiezheng Liu³, Yong Fu³, Yulan Hu², Kangmin Zhou², Minyun Zhou⁴, Yingying Hu² and Shunwei Zhu², ¹State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing
Background/Purpose: B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that contributes to the regulation of T cell, B cell and dendritic cell…
Abstract Number: 2696 • ACR Convergence 2025
Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
Eric Morand¹, Josefina Cortés-Hernández², Zahir AMOURA³, Julia Weinmann-Menke⁴, Britta Maurer⁵, Edouard Forcade⁶, Stephanie Finzel⁷, Jose Alvaro-Gracia⁸, Marc Scherlinger⁹, Alberta Hoi¹⁰, Yannick Muller¹¹, Rangi Kandane-Rathnayake¹², Ozana Fischer¹³, Beata Kovacs¹³, Frédérique Chaperon¹³, David Pearson¹³, Adrienne Lefeber¹⁴, Chih-Yung Sean Lee¹⁴, Jianping Yuan¹⁴, Vassilis Bitsikas¹³, Aditya Mahadevan Iyer¹⁵, Theodoulos Rodosthenous¹⁶, Melissa Fernandes¹³, Thomas Calzascia¹³, Richard Siegel¹³, Peter Gergely¹³ and Tamas Shisha¹³, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ³APHP, Paris, France, ⁴Department of Nephrology and Rheumatology and Center of Immunotherapy, Medical Center of the Johannes Gutenberg University, Mainz, Germany, ⁵Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ⁶CNRS-UMR ⁵¹⁶⁴ Immuno ConcEpT, Bordeaux University and Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, F-³³⁰⁰⁰, Bordeaux, France, ⁷Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁸Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Department of Rheumatology, Hospital General Universitario Gregorio Marañón and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, ⁹Department of Rheumatology, Hopitaux Universitaires de Strasbourg, Centre National de Référence RESO, Strasbourg, France, ¹⁰Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ¹¹Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, ¹²Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ¹³Novartis Biomedical Research, Basel, Switzerland, ¹⁴Novartis Biomedical Research, Cambridge, MA, ¹⁵Novartis Biomedical Research, Hyderabad, India, ¹⁶Novartis Pharmaceuticals UK Ltd, London, United Kingdom
Background/Purpose: Current evidence suggests that B cell depletion through CD19-directed chimeric antigen receptor T cell (CAR-T) therapies may offer promise in improving outcomes in severe…
Abstract Number: 2602 • ACR Convergence 2025
Cellular and molecular fine mapping in single-cell data pinpoints new immunopathology of systemic lupus erythematosus
Masahiro Nakano¹, Michihiro Kono¹, Kenichiro Asahara¹, Takayuki Katsuyama², Eri Katsuyama³, Takahiro Arakawa¹, Tsugumi Kawashima¹, Hajime Inokuchi¹, Takahiro Nishino¹, Haruka Takahashi¹, Bunki Natsumoto¹, Hiroaki Hatano¹, Yoshinori Matsumoto² and Kazuyoshi Ishigaki¹, ¹Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Yokohama, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with unknown etiology. While we previously identified key gene signatures of SLE using bulk RNA-seq…
Abstract Number: 2468 • ACR Convergence 2025
RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
Saira Sheikh¹, Vimal Derebail¹, Natalie Grovner¹, Gaurav Gulati², Mehrdad Abedi³, Meghan Sise⁴, Matthew Frigault⁴, Christopher Palma⁵, Patrick Reagan⁵, Cuoghi Edens⁶, Satya Kosuri⁶, Caitlin Elgarten⁷, Jon Burnham⁸, Jonathan Hogan⁹, Yvonne White⁹, Carl diCasoli⁹, Rebecca Estremera⁹, Jenell Volkov⁹, Daniel Nunez⁹, Fatemeh Hadi-Nezhad¹⁰, Thomas Furmanak⁹, Jason Stadanlick⁹, Larissa Ishikawa⁹, Zachary Vorndran⁹, Alexandra Ellis⁹, Jazmean Williams⁹, Steve Flanagan⁹, Quynh Lam¹⁰, Samik Basu⁹, Raj Tummala¹⁰ and David Chang⁹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of California, Davis School of Medicine, Davis, CA, ³University of California, Davis School of Medicine, Davis, ⁴Massachusetts General Hospital, Boston, MA, ⁵University of Rochester, Rochester, NY, ⁶University of Chicago, Chicago, IL, ⁷Children's Hospital of Philadelphia, Philadelphia, PA, ⁸Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁹Cabaletta Bio, Philadelphia, PA, ¹⁰Cabaletta Bio, Philadelphia
Background/Purpose: Current goals of treatment for systemic lupus erythematosus (SLE) are to achieve low disease state/remission, prevent flares, minimize organ damage, and decrease long-term morbidity…
Abstract Number: 2450 • ACR Convergence 2025
Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)
Irene Carrión-Barberà¹, Tarek Salman Montes², Laura Triginer³, Judit Font-Urgelles⁴, Anne Riveros frutos⁵, Sandra Garrote Corral⁶, Maria Garcia-Villanueva⁷, Carlos de Frías Polo⁸, María Galindo-Izquierdo⁹, Berta Magallares¹⁰, Andrea Hernández-martín¹¹, Jorge Juan Fragío Gil¹², Sebastián Sandoval Moreno¹³, Consuelo Ramos Giraldez¹⁴, Josefina Cortés-Hernández¹⁵, Elvira Díez García¹⁶, Clara Moriano¹⁷, Paloma Vela Casasempere¹⁸, M.Pilar Bernabeu Gonzalvez¹⁹, Irene Altabás-González²⁰, Samuel Hernández-Baldizón²¹, Leyre Riancho²², Inmaculada Ros Vilamajo²¹, Carlos Marras Fernández-Cid²³, Maria Piqueras García²⁴, Angel Garcia-Aparicio²⁵, marta Garijo Bufort²⁶, José Gomez-Puerta²⁷, Beatriz Frade Sosa²⁸, Silvia García Cirera²⁹, Vicenç Torrente-Segarra³⁰, Luis Sala³¹, Concepción Fito-Manteca³², Natividad del Val del amo³³, Julia Martínez Barrio³⁴, Jose Rosas Gómez de Salazar³⁵, Sergi Heredia³⁶, ana Urruticoechea-Arana³⁷, Anahy Maria Brandy³⁸, Maria Esther Uriarte³⁹, José María Pego-Reigosa⁴⁰ and Iñigo Rúa-Figueroa⁴¹, ¹Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ²Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ³Hospital del Mar, Barcelona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain, ⁶Hospital Ramón y Cajal, Madrid, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario ¹² de octubre, Madrid, Spain, ⁹Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ¹⁰Hospital de Sant Pau, Bareclona, ¹¹Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ¹²Hospital General Universitario, Valencia, Spain, ¹³Hospital Universitario Vall d’Hebron, Barcelona, Spain, ¹⁴Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ¹⁵Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ¹⁶Complejo Asistencial Universitario de León, León, Spain, ¹⁷Hospital León, LEON, Castilla y Leon, Spain, ¹⁸Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁹Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁰Complejo Hospitalario de Vigo, Vigo, Spain, ²¹Hospital Son Llàtzer, Palma de Mallorca, Spain, ²²Hospital de Sierrallana, Torrelavega, ²³Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁴Servicio Murciano de Salud, Murcia, Spain, ²⁵Hospital Universitario de Toledo, Toledo, Spain, ²⁶Rheumatology Department, Hospital de Sagunto, Spain, Valencia, Spain, ²⁷Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²⁸Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁹Consorci Coporació Sanitaria Parc Taulí, Sabadell, Spain, ³⁰Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ³¹Hospital Universitario de Torrejón, Madrid, Spain, ³²Rheumatology. Hospital Universitario de Navarra., Pamplona, Navarra, Spain, ³³Complejo Universitario de Navarra, Navarra, Spain, ³⁴Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ³⁵Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ³⁶Hospital Moisès Broggi, Barcelona, Spain, ³⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ³⁸Hospital Germans Trias i Pujol, Badalona, Spain, ³⁹Hospital Universitario Donostia, San Sebastian, Spain, ⁴⁰Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ⁴¹Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain
Background/Purpose: Anifrolumab is a biologic recently approved for systemic lupus erythematosus (SLE), with efficacy shown in trials, but data from real-world practice remain limited. The…
Abstract Number: 2433 • ACR Convergence 2025
The Clinical Utility of a Multianalyte Lupus Risk Score Incorporating Cell-bound Complement Activation Products: A Systematic Evaluation
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: Timely SLE diagnosis and treatment are critical to preventing irreversible organ damage and preserving quality of life. However, conventional biomarkers often underperform in patients…
Abstract Number: 2414 • ACR Convergence 2025
Autoantibody Clusters and SIGLEC1 are Predictive of Systemic Lupus Erythematosus Development
Alice Horisberger¹, Emily Oakes², Eilish Dillon³, Ifeoluwakiisi Adejoorin², Julia Caldropoli³, Kathryne Marks², Takanori Sasaki³, Farbod Moghaddam⁴, Paul Sciore⁵, Marvin J. Fritzler⁶, Deepak Rao², May Choi⁷ and Karen H. Costenbader⁸, ¹Lausanne University Hospital, University of Lausanne, Laussane, Switzerland, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴University of Calgary, Calgary, Canada, ⁵MitogenDx, Calgary, AB, Canada, ⁶MitognDx, Calgary, AB, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Up to a third of those with suspected SLE progress to definite SLE; however, reliable predictive markers for disease progression remain unknown. Previously, we…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].